Urology Research at the Michigan Institute of Urology
Products and Resources Prostate Cancer Information Packet

Share |



Welcome to Michigan Institute of Urology

The MIU Difference

Michigan Institute of Urology is the most comprehensive private practice urology group in Michigan.

We offer more fellowship-trained urological sub-specialists than any other group within the state of Michigan, more board certified urologists than any other group within the state of Michigan, our physicians have performed over 4000 robotic surgeries, our physicians have performed over 500 cryosurgeries for treatment of the prostate and kidney, and we have the greatest amount of experience with small single incision laparoscopic kidney and bladder surgery.

Learn more about the MIU Difference and take this opportunity to meet our Urologists.

Minimally Invasive Surgery

Minimally Invasive Surgery for the treatment of enlarged prostateprostate cancer, and kidney cancer.

Learn More >

Advanced BPH Treatments

Non-Surgical Treatment of enlarged prostate - An advanced BPH treatment that does not require surgery.

Learn More >

Robotic Surgery

Robotic Surgery performed by experienced surgeons for prostate and kidney cancer.

Learn More >

Urinary Control - Incontinence

Urinary Control (Incontinence) - A full range of options for male and female incontinence treatment.

Learn More >

Kidney Stone Disease

Kidney Stone Disease - Prompt evaluation and a variety of treatment options individualized to your specific needs.

Learn More >

MIU News


MIU is the first urology group in the United States to offer Apifiny (TM), the only tumor specific, non-PSA blood test designed to aid clinicians in the detection of prostate cancer. Learn More

MELVILLE, N.Y. -” FOR years, research on prostate cancer has sought an approach to screening that is more individualized than a one-size-fits-all measurement of the level of prostate-specific antigen in a man's blood. These efforts are now paying off.

That's why it's time to re-evaluate the nation's current approach to prostate cancer. Even though we anticipate 221,000 new diagnoses this year, and 28,000 deaths, recommendations drafted in 2010 and finalized in 2012 strongly discourage PSA screening men without symptoms for this disease.

Those decisions didn't take into account adaptations that urologists have made to help better identify patients likely to develop deadly prostate cancers. Some tools, called PSA derivatives, were being developed as early as the mid-1990s, and all have been refined since. READ MORE

More MIU News >

MIU Video Education

MIU is committed to providing a pathway to urologic health. We believe a critical component to the achievement of better health is education. We hope our web site provides added understanding of your conditions and treatments. Our video library is an extension of that commitment.

Robotic Prostate Surgery

Cryosurgery of the Prostate

More Urology Videos >